0000950170-23-071474.txt : 20231219 0000950170-23-071474.hdr.sgml : 20231219 20231219160537 ACCESSION NUMBER: 0000950170-23-071474 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231216 FILED AS OF DATE: 20231219 DATE AS OF CHANGE: 20231219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanford Svai S CENTRAL INDEX KEY: 0001591411 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40672 FILM NUMBER: 231497302 MAIL ADDRESS: STREET 1: C/O RANI THERAPEUTICS LLC STREET 2: 2051 RINGWOOD AVE. CITY: SAN JOSE STATE: CA ZIP: 95131 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Rani Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001856725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2051 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 BUSINESS PHONE: (408) 457-3700 MAIL ADDRESS: STREET 1: 2051 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 4 1 ownership.xml 4 X0508 4 2023-12-16 0001856725 Rani Therapeutics Holdings, Inc. RANI 0001591411 Sanford Svai S 2051 RINGWOOD AVE SAN JOSE CA 95131 false true false false Chief Financial Officer false Stock Option (Right to Buy) 5.44 2023-12-16 4 D false 171500 D 2033-03-26 Class A Common Stock 171500 34300 D Stock Option (Right to Buy) 2.84 2023-12-16 4 A false 171500 A 2033-03-26 Class A Common Stock 171500 171500 D Stock Option (Right to Buy) 13.21 2023-12-16 4 D false 58334 D 2032-03-21 Class A Common Stock 58334 41666 D Stock Option (Right to Buy) 2.84 2023-12-16 4 A false 58334 A 2032-03-21 Class A Common Stock 58334 58334 D Stock Option (Right to Buy) 9.44 2023-12-16 4 D false 83724 D 2031-07-28 Class A Common Stock 83724 127788 D Stock Option (Right to Buy) 2.84 2023-12-16 4 A false 83724 A 2031-07-28 Class A Common Stock 83724 83724 D The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023. The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022. The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021. Svai Sanford 2023-12-19